-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: July 2011
Bayh Dole Act a failure?
By Guest Writer Joseph Allen One hotly debated topic in Washington of real importance to the biotechnology community is how well the annual multi-billion dollar federal investment in R&D is being translated into new products, jobs and companies needed to improve the lives of US taxpayers and help pull the US economy out of its current doldrums. An interesting insight on the debate is captured in a Washington Post article “Innovation’s golden opportunity” that ran Read More >
Global Biotechnology IP Evaluation by Scientific American
Scientific American evaluated the strength of intellectual property in 48 countries (click on chart on top left side of story for data) in its Worldview Scorecard including a chart with country rankings. This data* is based on patentable inventions, membership of international treaties, duration of protection, enforcement mechanisms and restrictions (e.g., compulsory licensing). The U.S. holds the top spot, followed closely by Belgium, Canada, Denmark, Finland, France, Ireland, Italy, Japan, and the Netherlands (all tied Read More >
FDA: How can we improve it?
By Stephen Sherwin, Former Chairman of BIO As Congress and the President work together to hammer out a new, national economic roadmap, it is important to point out to those working in, and interested in, our industry that we too have recently assembled a roadmap – one designed to fully realize the promise our industry holds for people everywhere. Several weeks ago, at the 2011 BIO International Convention in Washington, DC, BIO unveiled its first ever 5 Read More >
Military Reliance on Oil Degrades Our National Security
Elizabeth L. King, Assistant Secretary of Defense for Legislative Affairs, last week wrote to the Senate Energy and Environment Committee about the importance of Sec. 526 of the Energy Independence and Security Act of 2007. This law requires that any alternative fuels purchased by the federal government be better from an environmental perspective than the petroleum-based fuels they’re currently purchasing. King noted: Further, repeal or exemption [of Section 526] could hamper the Department’s efforts to provide Read More >
Senate Hearing Focuses on Biobased Product Potential for Rural Job Creation
The Senate Agriculture Committee today held a hearing on “Growing Jobs in Rural America” (watch the webcast). Dr. Marc Verbruggen, President and CEO of NatureWorks LLC based in Wayzata, Minn., and Dr. Oliver P. Peoples, Founder and Chief Scientific Officer of Metabolix, Inc. based in Cambridge, Mass., both BIO members, testified about their companies’ plans for growth and job creation. Sen. Debbie Stabenow (D-Mich.), chair of the committee, “called the rural economy a bright spot Read More >
